CONGENITAL HYPOTHYROIDISM: AWARENESS, DIAGNOSIS AND TREATMENT IN PAEDIATRICS
People In Health Care
Associate Professor Michelle Jack, Paediatric Endocrinologist
Clinical Practice & Co-Lead Doctor of Medicine, Bond University, Queensland
Filmed Robina, Queensland | October 2024
Michelle Jack is Associate Professor of Clinical Practice, Faculty of Health Sciences & Medicine at Bond University, QLD, co-Head of Paediatrics and a Paediatric Endocrinologist at Lismore Base Hospital in NSW and Senior Staff Specialist, Paediatric Endocrinology, Northern New South Wales Local Health District.
Associate Professor Jack is a member of the ANZSPED Laboratory and Newborn Screening Sub-committee https://anzsped.org/subcommittees/lab-group/ and Thyroid working group https://anzsped.org/subcommittees/thyroid-working-group/.
Australian Health Journal spoke to Associate Professor Jack about congenital hypothyroidism and newborn screening and her concerns in the varying thresholds for across different states in Australia. Despite the existence of newborn screening programs since the 1970s, there is still controversy surrounding the appropriate screening levels. Congenital hypothyroidism, affecting about one in 3500 infants, can lead to severe intellectual and physical impairment if not diagnosed early. The condition is mainly caused by the thyroid gland’s failure to develop properly, resulting in insufficient thyroid hormone production.
The current challenge lies in setting the right screening thresholds to avoid false positive or missed diagnoses. Assoc Prof Jack highlights the need for standardisation in the approach to borderline thyroid abnormalities in children, as the wide variety of responses from paediatric endocrinologists indicates a lack of consensus. She emphasises the importance of conducting high-quality research to determine the optimal screening thresholds, considering both the impact on infants and their families and the healthcare system’s cost.
Associate Professor Jack is passionate about the health and wellbeing of children and adolescents, with diverse research areas including the impacts of family friendly workplace initiatives, screening and management of thyroid disorders in infants and children. She supports her First Nations colleagues on Indigenous-led research projects funded by the Medical Research Future Fund, aiming to improve the social and emotional wellbeing of First Nations Children. Through her clinical and academic roles, Michelle hopes to make a positive difference to the health and well-being of children and their families.
References on congenital hypothyroidism
ANZSPED website resources on congenital hypothyroidism
– https://anzsped.org/patient-resources/hormones-me-booklet-series/
– https://anzsped.org/patient-resources/anzsped-patient-flyers/)
Fifty years of newborn screening for congenital hypothyroidism: current status in Australasia and the case for harmonisation
-
From nurse, to roles in medtech marketing, championing women’s health
Aggie Cox is a senior healthcare marketing leader and women’s health advocate with over two decades of experience spanning clinical care, medical technology, and executive marketing leadership. She currently serves as Government Affairs & Marketing Director for Australia and New Zealand at Hologic, Inc., a global medical technology company dedicated to advancing women’s health through early detection, diagnosis, and treatment.
-
Inaugural report into Australasian Paramedicine Workforce Survey report to aid workforce planning
In a milestone for paramedicine, the Australasian College of Paramedicine earlier this year released the first report of a landmark three-year study identifying and exploring trends that affect the Australasian paramedicine workforce.
The inaugural Australasian Paramedicine Workforce Survey report 2023-24 explores the demographic, career trajectory, work motivations and conditions for those working in clinical, management and educational capacities within the paramedicine workforce of Australia and Aotearoa New Zealand. -
Being Part of the New Health Frontier
In November last year, the House of Representatives Standing Committee on Health, Aged Care and Sport delivered its bipartisan report “The New Frontier: Delivering better health for all Australians” on the approval processes for new drugs and novel medical technologies in Australia.
Australian Health Journal spoke to some of the industry bodies who were part of the Inquiry, for their comments on the process, the report and hopes in the recommendations being implemented.
